new weight loss injection retatrutide 🎙️ EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Education first 🤍 Retatrutide is

Home injection is more convenient and cost-effective than clinic visits

These compounds are not approved for human or veterinary use unless specifically noted in an approved drug context, such as tesamorelin for HIV-associated lipodystrophy

Simonson, B

[ Links ] 71

In studies using glutathione supplementation, typical doses range from 250 to 1,000 mg per day, and many supplements on the market typically provide around 500 mg per day

Of the 12 medications studied, seven are single agonists of GLP-1, four are dual agonists (including tirzepatide and three investigational agents that act on the GLP-1 and glucagon pathways), and one (retatrutide) is a triple agonist of the GLP-1, GIP, and glucagon pathways